VBI Vaccines (VBIV) PT Lowered to $5 at Canaccord Genuity

Canaccord Genuity analyst John Newman lowered the price target on VBI Vaccines (NASDAQ: VBIV) to $5.00 (from $10.00) while maintaining a Buy rating.

Analyst comments: "We maintain our BUY rating and are reducing our price target to $5 from $10 after moderating our launch estimate in the US due to less-clear competitive positioning vs Heplisav-B. We continue to believe Sci-B-Vac will be viewed positively by regulators and achieve approval in the US and EU after positive readout in CONSTANT later this year."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Sansera Engineering Ltd (SANSERA:IN) PT Raised to INR4,250 at ICICI Securities
• Indigo Paints (INDIGOPN:IN) PT Raised to INR1,300 at ICICI Securities